Magnetar Financial LLC Takes $723,000 Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Magnetar Financial LLC bought a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 13,498 shares of the company's stock, valued at approximately $723,000.

Several other large investors have also modified their holdings of JANX. Rhumbline Advisers increased its position in shares of Janux Therapeutics by 1.6% during the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock worth $2,043,000 after purchasing an additional 599 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Janux Therapeutics by 10.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock valued at $596,000 after buying an additional 1,095 shares during the last quarter. Virtu Financial LLC boosted its holdings in Janux Therapeutics by 48.0% in the third quarter. Virtu Financial LLC now owns 7,463 shares of the company's stock worth $339,000 after acquiring an additional 2,419 shares in the last quarter. Avanza Fonder AB acquired a new stake in Janux Therapeutics in the 4th quarter worth approximately $139,000. Finally, Zacks Investment Management boosted its stake in Janux Therapeutics by 8.7% in the 3rd quarter. Zacks Investment Management now owns 42,133 shares of the company's stock worth $1,914,000 after purchasing an additional 3,360 shares in the last quarter. Institutional investors own 75.39% of the company's stock.

Janux Therapeutics Stock Down 2.3 %

JANX stock traded down $0.71 during midday trading on Wednesday, hitting $30.12. The company's stock had a trading volume of 607,108 shares, compared to its average volume of 825,954. Janux Therapeutics, Inc. has a 52-week low of $28.92 and a 52-week high of $71.71. The firm has a 50-day simple moving average of $36.33 and a 200-day simple moving average of $46.31. The firm has a market capitalization of $1.78 billion, a P/E ratio of -25.74 and a beta of 3.23.

Remove Ads

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, sell-side analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on JANX shares. Lifesci Capital raised Janux Therapeutics to a "strong-buy" rating in a report on Friday, December 27th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $200.00 price target on shares of Janux Therapeutics in a report on Wednesday, December 11th. Leerink Partners raised their price target on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 price objective on shares of Janux Therapeutics in a report on Monday, March 3rd. Finally, Wedbush reissued an "outperform" rating and set a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $92.44.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,334 shares of the firm's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $42.29, for a total value of $140,994.86. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $3,473,658.31. This trade represents a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. bought 110,206 shares of the business's stock in a transaction dated Friday, March 7th. The shares were acquired at an average cost of $31.02 per share, for a total transaction of $3,418,590.12. Following the transaction, the director now directly owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. This represents a 1.10 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have sold 25,002 shares of company stock valued at $1,279,953. Insiders own 29.40% of the company's stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.